http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5801002-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f14d9668722225adaf294ef04414119e |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10S436-827 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10S436-813 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-574 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57423 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 |
| filingDate | 1995-11-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 1998-09-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7ce653710cb8df53f34eb5bd2586bd37 |
| publicationDate | 1998-09-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-5801002-A |
| titleOfInvention | Galactoside-binding-protein useful in the diagnosis and inhibition of of metastasis |
| abstract | Disclosed are novel polypeptides possessing part or all of the amino acid sequence or primary structural conformation and one or more of the biological properties of certain galactoside-binding-proteins with apparent molecular weights of 34,000 and 31,000. Genomic DNA, cDNA and manufactured DNA sequences coding for part or all of the sequences of amino acid residues of L-34-gal-lectin and L-31-gal-lectin are incorporated into vectors used to transform a host cell in culture. Also provided are antibodies against L-34-gal-lectin and L-31-gal-lectin and a method for inhibiting mammalian cell metastasis by treating mammalian cells in a living host with antibodies against L-34-gal-lectin or L-31-gal-lectin. A method of determining the metastatic potential of mammalian cells is also provided by which cells in vitro are contacted with antibodies against L-34-gal-lectin or L-31-gal-lectin which are labeled with a detectable probe. An elevated level of expression of L-34-gal-lectin or L-31-gal-lectin is indicative of metastatic potential. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-03071279-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2004077841-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-1325917-C http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7329542-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6770622-B2 |
| priorityDate | 1989-01-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 51.